Eli Lilly has launched its newly approved oral weight-loss pill, Foundayo, establishing a strong foothold in the competitive obesity drug market. With support from Amazon Pharmacy for same-day delivery, the company aims to capture significant market share against rivals like Novo Nordisk, which is also vying for dominance in the GLP-1 segment. Analysts anticipate Foundayo could generate between $1 billion to $2 billion in sales during its first year, bolstered by positive clinical trial results and strategic partnerships.
“ELI LILLY SAID YESTERDAY IT IS BUYING SOME TESTS.”
“IT IS IN THE CLINIC RIGHT NOW WITH A TREATMENT FOR SOME NARCOLEPSY, SLEEP DISORDER TREATMENTS.”
“THEIR BET IS SLEEP IS GOING TO BE A MULTIBILLION-DOLLAR MARKET ON THE ROAD, SO THEY'RE TRYING TO GET IN ON THE GROUND FLOOR.”
“$NVO Undercuts $LLY With High-Dose Wegovy at $399 a Month. Wegovy HD will cost $50 less than Zepbound.”
“Foundayo’s broader availability is set to further intensify the company’s ongoing battle with Novo to dominate the market for oral weight loss drugs.”
“1. Eli Lilly (LLY) – GLP-1 drugs (Mounjaro/Zepbound) targeting the $100B+ obesity market.”
“Apenas empezamos a ver el potencial de los agonistas GLP1/GIP. Eli Lilly tiene uno nuevo, de administración mensual (Brenipatide) y están efectuando algunos ensayos fascinantes.”
“Eli Lilly tiene uno nuevo, de administración mensual (Brenipatide) y están efectuando algunos ensayos fascinantes.”
“$LLY Back above the 200D, but no power so far.”
“Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India.”
“$LLY | Eli Lilly maintained at Overweight by Morgan Stanley, reflecting a positive outlook on the stock.”
“O Mounjaro (tirzepatide) teve a síntese patenteada pela Eli Lilly em 2016. Os primeiros estudos clínicos em humanos (fase 2) começaram em 2017. A aprovação da FDA para uso em humanos saiu em 13 de maio de 2022.”
